Abstract
Adenosine A2B and, much more importantly, adenosine A2A receptors modulate many physiological and pathological processes in the brain. In this review, the most recent evidence concerning the role of such receptors and their potential therapeutic relevance is discussed. The low affinity of A2B receptors for adenosine implies that they might represent a good therapeutic target, since they are activated only under pathological conditions (when adenosine levels raise up to micromolar concentrations). The availability of selective ligands for A2B receptors would allow exploration of such an hypothesis. Since adenosine A2A receptors mediate both potentially neuroprotective and potentially neurotoxic effects, their role in neurodegenerative diseases is highly controversial. Nevertheless, A2A receptor antagonists have shown clear antiparkinsonian effects, and a great interest exists on the role of A2A receptors in Alzheimer’s disease, brain ischaemia, spinal cord injury, drug addiction and other conditions. In order to establish whether such receptors represent a target for CNS diseases, at least two conditions are needed: the full comprehension of A2A-dependent mechanisms and the availability of ligands capable of discriminating among the different receptor populations.
Keywords: Adenosine A2B receptors, adenosine A2A receptors, Central Nervous System, drug target, neurodegeneration, neuroprotection, Adenosine A2B receptors, adenosine A2A receptors, Central Nervous System, drug target, neurodegeneration, neuroprotection, A2AR, A2BR, Alzheimer’s disease, Brain derived neurotrophic factor,
CNS & Neurological Disorders - Drug Targets
Title:Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
Volume: 11 Issue: 6
Author(s): Patrizia Popoli and Rita Pepponi
Affiliation:
Keywords: Adenosine A2B receptors, adenosine A2A receptors, Central Nervous System, drug target, neurodegeneration, neuroprotection, Adenosine A2B receptors, adenosine A2A receptors, Central Nervous System, drug target, neurodegeneration, neuroprotection, A2AR, A2BR, Alzheimer’s disease, Brain derived neurotrophic factor,
Abstract: Adenosine A2B and, much more importantly, adenosine A2A receptors modulate many physiological and pathological processes in the brain. In this review, the most recent evidence concerning the role of such receptors and their potential therapeutic relevance is discussed. The low affinity of A2B receptors for adenosine implies that they might represent a good therapeutic target, since they are activated only under pathological conditions (when adenosine levels raise up to micromolar concentrations). The availability of selective ligands for A2B receptors would allow exploration of such an hypothesis. Since adenosine A2A receptors mediate both potentially neuroprotective and potentially neurotoxic effects, their role in neurodegenerative diseases is highly controversial. Nevertheless, A2A receptor antagonists have shown clear antiparkinsonian effects, and a great interest exists on the role of A2A receptors in Alzheimer’s disease, brain ischaemia, spinal cord injury, drug addiction and other conditions. In order to establish whether such receptors represent a target for CNS diseases, at least two conditions are needed: the full comprehension of A2A-dependent mechanisms and the availability of ligands capable of discriminating among the different receptor populations.
Export Options
About this article
Cite this article as:
Popoli Patrizia and Pepponi Rita, Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581100
DOI https://dx.doi.org/10.2174/187152712803581100 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets Novel Insights into V-ATPase Functioning: Distinct Roles for its Accessory Subunits ATP6AP1/Ac45 and ATP6AP2/(pro) Renin Receptor
Current Protein & Peptide Science Preface:
Current Topics in Medicinal Chemistry Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling
Current Neuropharmacology Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research PET Imaging of Opioid Receptors in Pain: Progress and New Directions
Current Pharmaceutical Design Controlled Somatic and Germline Copy Number Variation in the Mouse Model
Current Genomics Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Current Drug Safety <i>Dichrostachys cinerea</i>: Ethnomedicinal Uses, Phytochemistry and Pharmacological Activities - A Review
The Natural Products Journal The Menstrual Cycle and Drug Metabolism
Current Drug Metabolism Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry Pathophysiological Role of Mitochondrial Potassium Channels and their Modulation by Drugs
Current Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology Editorial[Hot Topic:Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Caffeine as a Lead Compound for the Design of Therapeutic Agents for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Aspects of the Stability and Bioavailability of Carbohydrates and Carbohydrate Derivatives
Mini-Reviews in Medicinal Chemistry Roles of TRAF6 in Central Nervous System
Current Neuropharmacology